On Demand Webinar

Translational In Vitro & In Vivo Models for ADC Therapeutic Development

Antibody-Drug Conjugates (ADCs) have entered a renaissance period in oncology, offering the potential to deliver potent cytotoxic payloads with high specificity. However, the intricate mechanism of action required for a successful ADC relies on precise antigen binding, efficient internalization, lysosomal trafficking, and payload release. This complexity presents unique translational challenges that standard 2D models often fail to capture.

Watch this expert-led webinar to gain insight from Davy Ouyang, PhD, Senior Vice President of Innovation at Crown Bioscience, as he leverages over 20 years of drug discovery experience to explore advanced translational platforms optimized for ADC evaluation.

Watch a preview clip:

Drawing on a track record that includes driving first-in-class ADC programs and advancing over 20 IND-enabling molecules, Dr. Ouyang discusses how to bridge the gap between preclinical screening and clinical efficacy.

Dr. Ouyang highlights how integrating 3D organoids and Patient-Derived Xenografts (PDX) enables:

High-Fidelity Screening: Utilizing 3D tumor organoids to accurately assess antigen density, internalization rates, and cytotoxicity in a clinically relevant architecture.
Predictive In Vivo Validation: Leveraging PDX models that preserve patient-specific heterogeneity to evaluate pharmacokinetics, linker stability, and the "bystander effect" in a physiological context.
Accelerated Data Generation: Exclusive Feature: An introduction to the upcoming ADC-focused OrganoidXplore™ panel. Dr. Ouyang will detail how this large-scale screening platform fast-tracks lead selection, and registrants will receive an exclusive discount for their participation in the panel.

Whether you are optimizing linker technologies, evaluating novel payloads, or designing rational combination strategies, this webinar will offer essential guidance for selecting the right model systems to de-risk your program.

About the Presenter:

Davy Ouyang, PhD, Senior Vice President of Innovation, Crown Bioscience Inc.

Davy Ouyang is a seasoned biotech executive and scientific leader with over 20 years of experience in drug discovery and preclinical development across oncology, immuno-oncology, and autoimmune diseases. Davy serves as SVP of Innovation at Crown Bioscience following roles as Executive Vice President of R&D at Sidewinder Therapeutics and Vice President of Biology at InnoCare Pharma. Earlier in his career, Davy held research scientist positions at Merck & Co. and the Cancer Institute of New Jersey.

Dr. Ouyang has significant experience driving first-in-class ADC and biologics programs and a strong track record of advancing innovative drug candidates, including more than 20 IND-enabling molecules and 10 IND approvals across small molecules and biologics. Davy has extensive research experience, particularly in the areas of translational oncology, preclinical pharmacology, and platform development with a strong academic foundation and 44 peer-reviewed publications.

He received his PhD in Cancer Biology from the University of Hong Kong and completed postdoctoral training in oncology pharmacology with Dr. Cory Abate-Shen at Rutgers University.